BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 27389056)

  • 1. Exome sequencing identifies highly recurrent somatic GATA2 and CEBPA mutations in acute erythroid leukemia.
    Ping N; Sun A; Song Y; Wang Q; Yin J; Cheng W; Xu Y; Wen L; Yao H; Ma L; Qiu H; Ruan C; Wu D; Chen S
    Leukemia; 2017 Jan; 31(1):195-202. PubMed ID: 27389056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia.
    Greif PA; Dufour A; Konstandin NP; Ksienzyk B; Zellmeier E; Tizazu B; Sturm J; Benthaus T; Herold T; Yaghmaie M; Dörge P; Hopfner KP; Hauser A; Graf A; Krebs S; Blum H; Kakadia PM; Schneider S; Hoster E; Schneider F; Stanulla M; Braess J; Sauerland MC; Berdel WE; Büchner T; Woermann BJ; Hiddemann W; Spiekermann K; Bohlander SK
    Blood; 2012 Jul; 120(2):395-403. PubMed ID: 22649106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution.
    Hou HA; Lin YC; Kuo YY; Chou WC; Lin CC; Liu CY; Chen CY; Lin LI; Tseng MH; Huang CF; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF
    Ann Hematol; 2015 Feb; 94(2):211-21. PubMed ID: 25241285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C/EBPα and GATA-2 Mutations Induce Bilineage Acute Erythroid Leukemia through Transformation of a Neomorphic Neutrophil-Erythroid Progenitor.
    Di Genua C; Valletta S; Buono M; Stoilova B; Sweeney C; Rodriguez-Meira A; Grover A; Drissen R; Meng Y; Beveridge R; Aboukhalil Z; Karamitros D; Belderbos ME; Bystrykh L; Thongjuea S; Vyas P; Nerlov C
    Cancer Cell; 2020 May; 37(5):690-704.e8. PubMed ID: 32330454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific effects of somatic GATA2 zinc finger mutations on erythroid differentiation.
    Redondo Monte E; Leubolt G; Windisch R; Kerbs P; Dutta S; Landspersky T; Istvánffy R; Oostendorp RAJ; Chen-Wichmann L; Herold T; Cusan M; Schotta G; Wichmann C; Greif PA
    Exp Hematol; 2022 Apr; 108():26-35. PubMed ID: 35181392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GATA2 zinc finger 1 mutations are associated with distinct clinico-biological features and outcomes different from GATA2 zinc finger 2 mutations in adult acute myeloid leukemia.
    Tien FM; Hou HA; Tsai CH; Tang JL; Chiu YC; Chen CY; Kuo YY; Tseng MH; Peng YL; Liu MC; Liu CW; Liao XW; Lin LI; Lin CT; Wu SJ; Ko BS; Hsu SC; Huang SY; Yao M; Chou WC; Tien HF
    Blood Cancer J; 2018 Aug; 8(9):87. PubMed ID: 30190467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human leukemia mutations corrupt but do not abrogate GATA-2 function.
    Katsumura KR; Mehta C; Hewitt KJ; Soukup AA; Fraga de Andrade I; Ranheim EA; Johnson KD; Bresnick EH
    Proc Natl Acad Sci U S A; 2018 Oct; 115(43):E10109-E10118. PubMed ID: 30301799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ParaHox gene Cdx4 induces acute erythroid leukemia in mice.
    Thoene S; Mandal T; Vegi NM; Quintanilla-Martinez L; Rösler R; Wiese S; Metzeler KH; Herold T; Haferlach T; Döhner K; Döhner H; Schwarzmüller L; Klingmüller U; Buske C; Rawat VPS; Feuring-Buske M
    Blood Adv; 2019 Nov; 3(22):3729-3739. PubMed ID: 31770439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GATA factor switching from GATA2 to GATA1 contributes to erythroid differentiation.
    Suzuki M; Kobayashi-Osaki M; Tsutsumi S; Pan X; Ohmori S; Takai J; Moriguchi T; Ohneda O; Ohneda K; Shimizu R; Kanki Y; Kodama T; Aburatani H; Yamamoto M
    Genes Cells; 2013 Nov; 18(11):921-33. PubMed ID: 23911012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations of the GATA2 and CEBPA genes in paediatric acute myeloid leukaemia.
    Shiba N; Funato M; Ohki K; Park MJ; Mizushima Y; Adachi S; Kobayashi M; Kinoshita A; Sotomatsu M; Arakawa H; Tawa A; Horibe K; Tsukimoto I; Hayashi Y
    Br J Haematol; 2014 Jan; 164(1):142-5. PubMed ID: 24033149
    [No Abstract]   [Full Text] [Related]  

  • 11. Allele-specific expression of GATA2 due to epigenetic dysregulation in CEBPA double-mutant AML.
    Mulet-Lazaro R; van Herk S; Erpelinck C; Bindels E; Sanders MA; Vermeulen C; Renkens I; Valk P; Melnick AM; de Ridder J; Rehli M; Gebhard C; Delwel R; Wouters BJ
    Blood; 2021 Jul; 138(2):160-177. PubMed ID: 33831168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group.
    Theis F; Corbacioglu A; Gaidzik VI; Paschka P; Weber D; Bullinger L; Heuser M; Ganser A; Thol F; Schlegelberger B; Göhring G; Köhne CH; Germing U; Brossart P; Horst HA; Haase D; Götze K; Ringhoffer M; Fiedler W; Nachbaur D; Kindler T; Held G; Lübbert M; Wattad M; Salih HR; Krauter J; Döhner H; Schlenk RF; Döhner K
    Leukemia; 2016 Nov; 30(11):2248-2250. PubMed ID: 27375010
    [No Abstract]   [Full Text] [Related]  

  • 13. TET2 lesions enhance the aggressiveness of CEBPA-mutant acute myeloid leukemia by rebalancing GATA2 expression.
    Heyes E; Wilhelmson AS; Wenzel A; Manhart G; Eder T; Schuster MB; Rzepa E; Pundhir S; D'Altri T; Frank AK; Gentil C; Woessmann J; Schoof EM; Meggendorfer M; Schwaller J; Haferlach T; Grebien F; Porse BT
    Nat Commun; 2023 Oct; 14(1):6185. PubMed ID: 37794021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Molecular pathogenesis and therapeutic targets in acute erythroid leukemia].
    Takeda J
    Rinsho Ketsueki; 2022; 63(2):121-133. PubMed ID: 35264503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone demethylase LSD1-mediated repression of GATA-2 is critical for erythroid differentiation.
    Guo Y; Fu X; Jin Y; Sun J; Liu Y; Huo B; Li X; Hu X
    Drug Des Devel Ther; 2015; 9():3153-62. PubMed ID: 26124638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor necrosis factor alpha inhibits erythroid differentiation in human erythropoietin-dependent cells involving p38 MAPK pathway, GATA-1 and FOG-1 downregulation and GATA-2 upregulation.
    Buck I; Morceau F; Cristofanon S; Heintz C; Chateauvieux S; Reuter S; Dicato M; Diederich M
    Biochem Pharmacol; 2008 Nov; 76(10):1229-39. PubMed ID: 18805401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GATA-1 and erythropoietin receptor genes are highly expressed in erythroleukemia.
    Komatsu N; Kirito K; Izumi T; Eguchi M; Miura Y
    Exp Hematol; 1998 Nov; 26(12):1148-54. PubMed ID: 9808054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects on gene transcription and hematopoietic differentiation correlate with GATA2 mutant disease phenotypes.
    Chong CE; Venugopal P; Stokes PH; Lee YK; Brautigan PJ; Yeung DTO; Babic M; Engler GA; Lane SW; Klingler-Hoffmann M; Matthews JM; D'Andrea RJ; Brown AL; Hahn CN; Scott HS
    Leukemia; 2018 Jan; 32(1):194-202. PubMed ID: 28642594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenic GATA2 genetic variants utilize an obligate enhancer mechanism to distort a multilineage differentiation program.
    Katsumura KR; Liu P; Kim JA; Mehta C; Bresnick EH
    Proc Natl Acad Sci U S A; 2024 Mar; 121(10):e2317147121. PubMed ID: 38422019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Classification of CEBPA mutated acute myeloid leukemia by GATA2 mutations.
    Marceau-Renaut A; Guihard S; Castaigne S; Dombret H; Preudhomme C; Cheok M
    Am J Hematol; 2015 May; 90(5):E93-4. PubMed ID: 25611491
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.